Aardvark Therapeutics specializes in small molecule therapeutics for obesity and rare genetic metabolic disorders.
Aardvark Therapeutics has raised $85.0M in total funding. The most recent round was Series C. The last funding was announced in May 2024.
Aardvark Therapeutics's investors include Cormorant Asset Management, Walleye Capital, Decheng Capital, Premier Partners, Vickers Venture Partners.
Aardvark Therapeutics is headquartered in San Diego, United States.
Aardvark Therapeutics specializes in small molecule therapeutics for obesity and rare genetic metabolic disorders.
Aardvark Therapeutics is at the Series C stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Aardvark Therapeutics — Funding & Investors." VCBacked, May 9, 2024, https://www.vcbacked.co/company/aardvark-therapeutics. Accessed July 19, 2026.
VCBacked. (2024). Aardvark Therapeutics — Funding & Investors. Retrieved July 19, 2026, from https://www.vcbacked.co/company/aardvark-therapeutics
{{cite web |title=Aardvark Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/aardvark-therapeutics |website=VCBacked |access-date=July 19, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated